• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Abbott earns FDA green light for next-gen CardioMEMS pulmonary artery pressure reader

Abbott earns FDA green light for next-gen CardioMEMS pulmonary artery pressure reader

February 27, 2026 By Sean Whooley

Abbott CardioMEMS Hero device
The CardioMEMS Hero device for pulmonary artery pressure readings. [Image courtesy of Abbott]
Abbott (NYSE: ABT) announced today that the FDA approved its CardioMEMS Hero next-generation pulmonary artery (PA) pressure reader.

CardioMEMS Hero features new design features to empower heart failure patients and clinicians with daily insights for detecting and combating heart failure progression. It represents a new component of the company’s CardioMEMS HF system.

Abbott plans to begin the commercial release of the CardioMEMS Hero reader in the U.S. soon.

Remote monitoring technologies like the Abbott CardioMEMS sensor enable better management of heart failure. The CardioMEMS sensor’s design enables it to help people and their physicians proactively manage heart failure. It also helps to potentially prevent events that could lead to hospitalization.

CardioMEMS is implanted into the pulmonary artery via a minimally invasive procedure. The paperclip-sized sensor wirelessly transmits data about heart rates and pressures to the patient’s physicians. This continuous data stream aids in adjusting treatment plans and keeping hospital admissions at bay.

The technology first received FDA approval in 2014 for Class III heart failure patients hospitalized for the condition within the previous year. In February 2022, it received an expanded indication that could reach an additional 1.2 million people with heart failure.

More about the Abbott CardioMEMS Hero system

Abbott says CardioMEMS Hero is similar in size to a laptop case and sleeker and smaller than the system’s previous model. It works with the sensor to take a remote PA pressure reading and securely send data to their care team.

Clinicians can receive daily data readings and, if they see changes in PA pressures, communicate to the patient any medication or lifestyle changes necessary to help slow heart failure progression. This can occur before a patient even feels symptoms, keeping them out of the hospital.

Features of Hero include a 60% lighter device compared to the previous model for easy use every day. Abbott designed it to fit inside of a carry-on suitcase too, making travel more convenient.

Additionally, Hero enables a consistent reading position for reliable, accurate results. Abbott said it’s the only patient reader integrated with Wi-Fi and cellular connectivity for easy setup and virtual readings anywhere they have a signal.

“Abbott’s CardioMEMS Hero reader is modernizing a proven and effective remote patient management system, making it even more convenient for patients to use a device that has shown a 57% reduction in heart failure hospitalizations,” said Dr. Finn Gustafsson, chief medical officer and divisional VP of Abbott’s Heart Failure business. “With this new reader, people can work with their doctors to proactively manage their condition outside of the doctor’s office even more efficiently – increasing convenience and the patient experience.”

Filed Under: Cardiac Implants, Cardiovascular, Diagnostics, Featured, Health Technology, Implants, Patient Monitoring, Structural Heart Tagged With: Abbott, FDA

More recent news

  • Siemens Healthineers debuts Accela single-breath radiotherapy system
  • GE HealthCare hires chief AI officer from Medtronic
  • Former Teleflex CEO to lead Inspire competitor Nyxoah
  • Retired Stryker leader Tim Scannell dies at 62
  • HighLife raises more than $90M to advance its TMVR system

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy